{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T10:15:10Z","timestamp":1720779310155},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1684\/bdc.2011.1445","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T20:01:59Z","timestamp":1565726519000},"page":"S69-S78","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S","title":["Gestion des effets secondaires des th\u00e9rapies cibl\u00e9es dans le cancer du rein : effets secondaires digestifs"],"prefix":"10.1016","volume":"98","author":[{"given":"Jean-Louis","family":"Davin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Ducrott\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Hou\u00e9d\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1684\/bdc.2011.1445_bib0005","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10238-007-0145-8","article-title":"Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib","volume":"7","author":"Porta","year":"2007","journal-title":"Clin Exp Med"},{"key":"10.1684\/bdc.2011.1445_bib0010","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/SPC.0b013e32832e4681","article-title":"Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma","volume":"3","author":"Guevremont","year":"2009","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1684\/bdc.2011.1445_bib0015","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1684\/bdc.2011.1445_bib0020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2011.1445_bib0025","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","article-title":"Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1445_bib0030","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1093\/jnci\/djn319","article-title":"Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial","volume":"100","author":"Eisen","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1684\/bdc.2011.1445_bib0035","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2011.1445_bib0040","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1558-7673(11)70151-3","article-title":"Phase III study of sunitinib malate (SU11248) versus interferon-alpha as first-line treatment in patients with metastatic renal cell carcinoma","volume":"5","author":"Reddy","year":"2006","journal-title":"Clin Genitourin Cancer"},{"key":"10.1684\/bdc.2011.1445_bib0045","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1445_bib0050","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2011.1445_bib0055","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1684\/bdc.2011.1445_bib0060","doi-asserted-by":"crossref","first-page":"C914","DOI":"10.1152\/ajpcell.1996.271.3.C914","article-title":"Epidermal growth factor inhibits Ca(2+)-dependent Cl- transport in T 0420 human colonic epithelial cells","volume":"271","author":"Uribe","year":"1996","journal-title":"Am J Physiol"},{"key":"10.1684\/bdc.2011.1445_bib0065","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.coph.2004.05.004","article-title":"Growth factors and trefoil peptides in gastrointestinal health and disease","volume":"4","author":"Playford","year":"2004","journal-title":"Curr Opin Pharmacol"},{"key":"10.1684\/bdc.2011.1445_bib0070","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ejca.2005.11.014","article-title":"Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: is rash associated with treatment outcome?","volume":"42","author":"Strumberg","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1684\/bdc.2011.1445_bib0075","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/ncponc1087","article-title":"Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy","volume":"5","author":"Loriot","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"issue":"supplements 5","key":"10.1684\/bdc.2011.1445_bib0080","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1359-6349(07)70110-6","article-title":"Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse-event management","author":"N\u00e9grier","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1684\/bdc.2011.1445_bib0085","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1548-5315(11)70751-3","article-title":"Managing the side effects of sorafenib and sunitinib","volume":"3","author":"Wood","year":"2006","journal-title":"Commun Oncol"},{"key":"10.1684\/bdc.2011.1445_bib0090","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10269-009-1069-6","article-title":"Les effet secondaires des anti-angiog\u00e9niques","volume":"11","author":"Chevreau","year":"2009","journal-title":"Oncologie"},{"key":"10.1684\/bdc.2011.1445_bib0095","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.eururo.2007.11.037","article-title":"Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma","volume":"53","author":"Bhojani","year":"2008","journal-title":"Eur Urol"},{"key":"10.1684\/bdc.2011.1445_bib0100","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1634\/theoncologist.2008-0120","article-title":"Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies","volume":"13","author":"Hutson","year":"2008","journal-title":"Oncologist"},{"key":"10.1684\/bdc.2011.1445_bib0105","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jpainsymman.2007.10.007","article-title":"Evaluation and management of treatment-related diarrhea in patients with advanced cancer: a review","volume":"36","author":"Cherny","year":"2008","journal-title":"J Pain Symptom Manage"},{"key":"10.1684\/bdc.2011.1445_bib0110","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1200\/JCO.2008.21.6994","article-title":"Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma","volume":"28","author":"Hutson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1445_bib0115","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ctrv.2008.12.003","article-title":"Tolerability of first-line therapy for metastatic renal cell carcinoma","volume":"35","author":"Porta","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"10.1684\/bdc.2011.1445_bib0120","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.clpt.2006.04.007","article-title":"Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer","volume":"80","author":"Lu","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1684\/bdc.2011.1445_bib0125","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1111\/j.1572-0241.2008.01982_19.x","article-title":"Sorafenib-induced liver failure","volume":"103","author":"Schramm","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1684\/bdc.2011.1445_bib0130","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1592\/phco.28.8.1066","article-title":"Sunitinib-related fulminant hepatic failure: case report and review of the literature","volume":"28","author":"Mueller","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1684\/bdc.2011.1445_bib0135","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1548-5315(11)70508-3","article-title":"Hepatic injury associated with bevacizumab use in metastatic breast and colon cancers: a review of two cases","volume":"5","author":"Brown-Glaberman","year":"2008","journal-title":"Community Oncology"},{"key":"10.1684\/bdc.2011.1445_bib0140","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1634\/theoncologist.2009-0088","article-title":"Sorafenib and sunitinib","volume":"14","author":"Kim","year":"2009","journal-title":"Oncologist"},{"key":"10.1684\/bdc.2011.1445_bib0145","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1200\/JCO.2008.20.0931","article-title":"Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301","volume":"27","author":"Miller","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115305270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115305270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T08:35:23Z","timestamp":1602491723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455115305270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0007455115305270"],"URL":"https:\/\/doi.org\/10.1684\/bdc.2011.1445","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}